I nt rod u ct i o n
ver the last quarter ce nt u ry, dissolution te s ting has emerged as a highly valuable in-vitro test to chara cte ri ze the pe rfo rm a n ce of a dosage fo rm .The po p u l a ri ty of dissolution te s ting is based on the fact that solubilization of a d rug in gastro i ntestinal fluid is a pre re q u i s i te fo r the drug to be absorbed and available to the systemic circ u l at i o n .The dissolution testing is pe rfo rmed as a re l at i vely fast and inex pe n s i ve te c hnique to eva l u ate pharm a ce u t i cal dosage fo rm s be fo re they are te s ted in clinical tri a l s. It is pru d e nt to have exte n s i ve dissolution data to maximize the c h a n ces for success in bioava i l a b i l i ty testing in h u m a n s.
Dissolution testing can be used: (1) to dete ct the i n f l u e n ce of cri t i cal fo rm u l ation and manufact u ri n g va riables in Fo rm u l ation & Deve l o p m e nt and Re s e a rch & Deve l o p m e nt ; (2) to assist in select i o n of a best fo rm u l at i o n ; (3) to check the changes during stability studies; (4) to establish final dissolution s pe c i f i cations for the pharm a ce u t i cal dosage fo rm ; (5) to develop IVIVC [1]; (6) as a quality co nt rol too l ; and (7) to establish the similari ty of pharm a ce u t i ca l dosage fo rm s, for which co m po s i t i o n ,m a n u f a ct u ring site, s cale of manufact u re, m a n u f a ct u ri n g p rocess and/or equipment may have changed within defined limits [2, 3] .
Dissolution testing can be used as a surrog ate fo r b i o ava i l a b i l i ty and bioe q u i va l e n ce under some conditions such as minor fo rm u l ation or equipm e nt changes, multiple strengths of the same dru g p rod u ct, m a n u f a ct u ring site changes, b atc h s ca l e -u p, and justifying dissolution spe c i f i cat i o n range [4] . In some ca s e s, b i o ava i l a b i l i ty needs to be d e m o n s t rated only 'if the prod u ct fails to achieve a d e q u ate dissolution when co m p a red to a stand a rd ' [ 5 ] .The US FDA re q u i res that dissolution dat a be included for a new drug application (NDA) and an abbrev i ated new drug application (ANDA) submission for bioe q u i va l e n ce rev i e w.
To the pharm a ce u t i cal re s e a rchers invo l ved in dissolution testing of dosage fo rm s, the similari ty f a ctor f 2 is not unkn ow n . After int rod u ction of this f a ctor by Moo re and Flanner [6] , it has been adopted by the Ce nter for Drug Eva l u ation and Re s e a rc h (US FDA) and by Human Medicines Eva l u ation Un i t of The Eu ro pean Ag e n cy for the Eva l u ation of Medicinal Prod u cts (EMEA) as a cri te rion for the a s s e s s m e nt of the similari ty be tween two dissolution pro f i l e s. It is included in va rious guidance docu m e nts [2, 3 ,7 -9 ] .
The similari ty factor f 2 as defined by FDA and EMEA is a log a rithmic re c i p rocal square root tra n sfo rm ation of one plus the mean squared (the ave rage sum of squares) diffe re n ces of drug pe rce nt d i s s o l ved be tween the test and re fe re n ce prod u ct s :
( 1 ) w h e re n is the number of dissolution time po i nt s, and R t and T t a re the re fe re n ce and test dissolution values (mean of at least 12 dosage units) at time t.
When the two dissolution profiles are ident i ca l , f 2 = 50 x log (100) = 100, and when the dissolution of one prod u ct (test or re fe re n ce) is co m p l e te d be fo re the other be g i n s, f 2 = 50 x log { [ 1 + 1/n ∑ ( 1 0 0 ) 2 ] -0 . 5 x 100 } = -0.001, which can be ro u n d e d to 0.Thus the value of f 2 ranges from 0 to 100. A higher f 2 value indicates closeness be tween the two dissolution pro f i l e s.The equation of f 2 is only a p p l i cable in co m p a ring curves in which the ave r-age diffe re n ce be tween R and T is less than 100 [6] . In other wo rd s, the amount of drug released shall be ex p ressed in pe rce nt .
Shah et al [10] re po rted that an ave rage diffe re n ce of no more than 10% at any sampling time po i nt be tween re fe re n ce and te s t p rod u cts may be acce p t a b l e.Th e authors further stated that when this 10% ave rage absolute diffe re n ce is substituted in the equat i o n , f 2 be comes 50. As per curre nt guida n ce doc u m e nt s, two dissolution p rofiles are co n s i d e red 's i m i l a r' when the f 2 value is be tween 50 and 100.The rationale for prov i ding this acceptable range is that in a real life situat i o n , it is not ex pe cted to have f 2 value be 100 eve n when the two dissolution pro f i l e s a re generated from the same b atch due to int ra -b atch va ri at i o n .
As per curre nt understanding, if the pe rce nt d rug released from re fe re n ce prod u ct is 15 at time t, a range of 5 to 25 is pe rmissible for the test produ ct at the same time po i nt . In our opinion, the curre nt lower limit of f 2 is ve ry libe ra l ,e s pecially fo r sustained release (SR) fo rm u l at i o n s.This can be explained by taking two hy po t h e t i cal ex a m p l e s. Consider two SR release pro f i l e s, one is a 12 hr ze ro -o rder profile and the other is a 24 hr ze ro -o rder profile as the re fe re n ce release pro f i l e s (Table 1 and 2). Table 1 and 2 also show the pe rce nt dev i ation allowe d, as per the curre nt unders t a n d i n g. One would find that this pe rce nt dev i ation is ve ry high. For ex a m p l e, for the 12 hr ze roo rder release profile up to ±40% and for the 24 hr ze ro -o rder release profile up to ±80% dev i ation is a l l owed in the initial phase (i.e. up to 3 hr). This is ve ry cri t i cal especially for the SR fo rm u l ations of the drug with narrow thera peutic index .
In bioe q u i va l e n ce studies of SR prod u ct s, one of the object i ves is to doc u m e nt that the prod u ct d oes not release the drug too rapidly (dose dump) [ 1 1 ] . Due to many re a s o n s, the po s s i b i l i ty of dev i ation in in-vivo testing is ve ry high as co m p a red to t h at in in-vitro te s t i n g. De s p i te this po s s i b i l i ty, t h e c u rre nt allowable limit for the bioe q u i val e n ce s t u dy is 80 -125% [12] .
If 10% dev i ation with re s pe ct to the dissolution p rofile of re fe re n ce prod u ct is to be allowed fo r dissolution profiles to be similar, the lower limit fo r f 2 value is to be ca l c u l ated as shown in Table 3 and 4 .The f 2 values we re ca l c u l ated using equation 1. The genera l i zed equation to estimate the lowe r a c ceptable value of f 2 (f 2 L X ) is shown be l ow where X is the pe rce nt dev i ation (e. g. 2 ,5 ,1 0 ,e tc ) .
( 2 )
The lower acceptable f 2 (f 2 L 1 0 ) values we re ca l c ul ated for a large number of dissolution data sets g e n e rated in our labo rato ry as well as for published wo rk [ 1 3 -1 7 ] . It was found that the f 2 L 1 0 va l u e was depe n d e nt on individual data set, which indicates that no general acceptable limit can be sugg e s te d. Table 5 shows the values of f 2 and f 2 L X fo r the 12 hr and 24 hr ze ro -o rder release pro f i l e s. If one intends to suggest a lower acceptable value of f 2 for 12 hr or 24 hr ze ro -o rder release pro f i l e, a value of 60 may be suggeste d.This value is 20% Refinement of Similarity Factor f 2 … continued higher than the curre ntly used value of 50.We also would like to po i nt out that, as per curre nt theory, i n s tead of 10%, a p p rox i m ately 16% dev i ation is a l l owed be tween two dissolution profiles to be s i m i l a r. The curre ntly pro posed libe ral appro a c h widens the acce p t a n ce cri te ria and may inadve rte ntly lead to the declaration of similari ty of dissolution profiles which otherwise are quite dissimilar. S U PAC-MR guidance states that the ave rage diffe re n ce at any dissolution time po i nt be tween te s t and re fe re n ce mean profiles should not exce e d 15% [3] . Ac co rding to curre nt theory, the f 2 va l u e of 50 allows more than 15% dev i ation at many time po i nts for the 12 hr and 24 hr ze ro -o rd e r release pro f i l e s. In other wo rd s, the curre nt lowe r a c ceptable limit of f 2 value (i.e. 50) violates the S U PAC -MR guideline.
It is also impo rt a nt to note that as per curre nt t h e o ry, a negat i ve value for pe rce nt drug re l e a s e d is enco u nte red for the test prod u ct (Table 1 and 2), which is pra ct i cally impo s s i b l e.This situat i o n ,h oweve r, is not enco u nte red in the pro posed method to ca l c u l ate lower limit of f 2 .
Conclusion
A wide range of methods is available for the co m p a rison of dissolution pro f i l e s.The method p ro posed by Moo re and Flanner is most po p u l a r be cause it is re commended in the US FDA and the EMEA guidance doc u m e nt s. In our opinion, t h e l ower acce p t a n ce limit for the f 2 value is not pro pe rly set. A new co n cept for finding the acce p t a b l e limit for the f 2 value and an equation to ca l c u l ate it has been propo s e d.We would like to bring the kind notice of va rious re g u l ato ry co m m i t tees to redefine the curre nt acce p t a n ce limit of the simil a ri ty factor f 2 .Ph a rm a ce u t i cal fo rm u l ators may consider the theory s u g g e s ted in this article while m a king decisions re g a rding simil a ri ty of bo rder line ca s e s. Table 5 .Ca l c u l ated f 2 and f 2 L X values for 12 and 24 hr ze ro -o rd e r release profiles at diffe re nt pe rce nt dev i at i o n .
